| Ruconest (conestat alfa) / SOBI, Pharming Group |
NCT04705831: Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection |
|
|
| Recruiting | 4 | 40 | US | Ruconest | IMMUNOe Research Centers | Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19 | 01/22 | 01/22 | | |
| Recruiting | 2 | 150 | Switzerland, Europe and US | Ruconest (conestat alfa) - SOBI, Pharming Group | Pharming Group, Cytobioteck, HyupJin Corporation, SOBI, Megapharm, Bausch Health | Covid-19 | | | | |
2016-005083-34: Conestat alfa as prophylactic treatment for idiopathic non-histaminergic acquired angioedema Conestat alfa (Ruconest®) behandeling voor het voorkómen van angio-oedeem aanvallen bij patiënten met angio-oedeem met onbekende oorzaak |
|
|
| Ongoing | 2 | 10 | Europe | Ruconest, Powder for solution for injection, Ruconest 2100 U powder for solution for injection | University Medical Center Utrecht, Pharming Group N.V., | The medical condition to be investigated is idiopathic non-histaminergic angioedema (InH-AAE). This disease is characterized by recurrent episodes with swelling of the subcutis and mucous membranes. Patient with InH-AAE have by defenition no wheals and are nonresponsive to anti-histamine therapy. Het te onderzoeken ziektebeeld is idiopatisch non-histaminerg verworven angio-oedeem (InH-AAE). Deze aandoening wordt gekenmerkt door recidiverende episodes met zwellingen in de subcutis en mucosa. InH-AAE patienten hebben per definitie geen urticaria en reageren niet op antihistaminica., The medical condition to be investigated is idiopathic non-histaminergic angioedema (InH-AAE). This disease is characterized by recurrent episodes with swelling of the skin and mucous membranes. Het te onderzoeken ziektebeeld is idiopatisch non-histaminerg verworven angio-oedeem (InH-AAE). Deze aandoening wordt gekenmerkt door recidiverende episodes met zwellingen in de subcutis en mucosa., Diseases [C] - Immune System Diseases [C20] | | | | |
2018-002904-14: A study to investigate the tolerance and safety of treatment in patients with preeclampsia Een studie om de tolerantie en veiligheid van behandeling van patienten met zwangerschapsvergiftiging te onderzoeken. |
|
|
| Not yet recruiting | 2 | 30 | Europe | Ruconest, Powder for solution for injection, Ruconest | Pharming Technologies B.V., Pharming Technologies B.V. | Preeclampsia Pre-eclampsie, Preeclampsia Zwangerschapsvergiftiging, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
| Terminated | 2 | 29 | Europe | conestat alfa or placebo, Ruconest | Pharming Technologies B.V. | Non-ST Elevation Myocardial Infarction (NSTEMI) | 04/23 | 04/23 | | |
PAIR-TAVI, NCT05145283: Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation |
|
|
| Recruiting | 2 | 250 | Europe | Conestat alfa (Ruconest®), NaCl 0.9%) | University Hospital, Basel, Switzerland, Swiss National Science Foundation, Pharming Technologies B.V. | Acute Ischemic Stroke, Acute Renal Injury | 03/25 | 03/25 | | |
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks |
|
|
| Recruiting | N/A | 300 | Europe, RoW | rhC1INH or pdC1INH, Ruconest | Pharming Technologies B.V. | Hereditary Angioedema | 01/25 | 01/25 | | |